Q-omics provides the consensus-scored PTOV1-AS2 profile across patient tissues and cancer cell-line models. PTOV1-AS2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PTOV1-AS2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, PTOV1-AS2 RNA expression shows 18,619 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where PTOV1-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTOV1-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTOV1-AS2 survival associations across molecular data types. PTOV1-AS2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTOV1-AS2 RNA expression–survival associations across cancer types. High PTOV1-AS2 expression shows unfavorable associations in KIRC, ACC and LGG, but favorable associations in HNSC, PAAD and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PTOV1-AS2 RNA expression.
This table summarizes PTOV1-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PTOV1-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTOV1-AS2 shows higher tumor expression in COAD, HNSC, STAD, KIRC, LIHC and BLCA. The COAD box plot shows higher PTOV1-AS2 RNA expression in tumor versus normal tissue (log2 FC = +1.507, t-test p < 0.001).
This table shows molecular features associated with PTOV1-AS2 in patient tissues and cancer cell lines. In patient samples, PTOV1-AS2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTOV1-AS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
